Eric M. Ostertag
Medical Practice at 2 St, Lexington, KY
License number
Kentucky 42429
Issued Date
Mar 19, 2009
Expiration Date
Feb 29, 2012
Category
Pathology
Type
Research
Address
Address
535 W Second St SUITE L102, Lexington, KY 40508
Education
University of Pennsylvania School of Medicine, Philadelphia, 2002
Phone
(267) 259-1086 (Work)
Personal information
See more information about Eric M. Ostertag at radaris.comName
Address
Phone
2824 Belle Haven Pl, Lexington, KY 40511
622 W Main St #112, Lexington, KY 40508
Professional information
See more information about Eric M. Ostertag at trustoria.com
Ceo At Transposagen Biopharmaceuticals Inc.
Ceo At Transposagen Biopharmaceuticals Inc.
Position:
CEO at Transposagen Biopharmaceuticals Inc.
Location:
Lexington, Kentucky Area
Industry:
Biotechnology
Work:
Transposagen Biopharmaceuticals Inc.
since 2003
-
CEO
PhenoTech
2005 - 2006
-
Executive Vice President
Hospital of the University of Pennsylvania
2004 - 2005
-
Transfusion Medicine Fellow
Hospital of the University of Pennsylvania
2002 - 2003
-
Clinical Pathology Resident
Education:
University of Pennsylvania School of Medicine 1995 - 2002
University of Wisconsin-Madison 1991 - 1995
University of Wisconsin-Madison 1991 - 1995
Skills:
Molecular Biology, Drug Discovery, Genetics, Stem Cells, Animal Models, DNA, Hardware Diagnostics, Biotechnology, Lifesciences, Genomics, Cell Culture, Pharmaceutical Industry, Gene Therapy, Immunology, Cell Biology, PCR, Microbiology, Nanotechnology, Biochemistry, Cell, Drug Development, Research, Business Strategy, New Business Development
Honor & Awards:
Howard Hughes Predoctoral Fellow
Predoctoral Basic Science Award from American Society of Human Genetics (for best genetics research in country by a graduate student)
O.H. Perry Pepper Award from University of Pennsylvania School of Medicine (for best overall combined clinical and research skills)
Best Abstract Award from the American Society for Apheresis (for work on rare disease called Thrombotic Thrombocytopenic Purpura)
Languages:
Spanish
Biodegradable Nanoparticles As Novel Hemoglobin-Based Oxygen Carriers And Methods Of Using The Same
Biodegradable Nanoparticles As Novel Hemoglobin-Based Oxygen Carriers And Methods Of Using The Same
US Patent:
2011025, Oct 20, 2011
Filed:
Apr 19, 2011
Appl. No.:
13/090076
Inventors:
P. Peter Ghoroghchian - Philadelphia PA, US
Eric Ostertag - Lexington KY, US
Eric Ostertag - Lexington KY, US
Assignee:
Vindico NanoBio Technology Inc. - Lexington KY
International Classification:
A61K 9/14, A61K 38/02, A61K 31/70, A61K 38/42, A61P 7/00, A61P 35/00, A61P 17/02, A61K 9/00, A61K 31/7088, B82Y 5/00
US Classification:
424489, 424400, 514 11, 514 23, 514 44 R, 514 135, 977773, 977915
Abstract:
Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties.
Genetically Modified Rat Models For Pain
Genetically Modified Rat Models For Pain
US Patent:
2012015, Jun 14, 2012
Filed:
Aug 20, 2010
Appl. No.:
13/391309
Inventors:
Eric M. Ostertag - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Karin Westlund High - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Karin Westlund High - Lexington KY, US
International Classification:
A61K 49/00, C12Q 1/02, A01K 67/027
US Classification:
800 3, 800 14, 435 29
Abstract:
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in altered nervous system function. In one aspect, the altered function results in pain in the mammal. In another aspect, the nervous system dysfunction results in prolonged hyperalgesia, allo dynia, and loss of sensory function. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of altered nervous system function mediated pain and methods of their use. In another aspect, the genetically modified rats, as well as the descendants and ancestors of such animals, are animal models of nervous system dysfunction resulting in prolonged hyperalgesia, allodynia, and loss of sensory function and methods of their use. In another aspect, the present invention provides a method of identifying a compound useful for the treatment or prevention of pain.
Genetically Modified Rat Comprising A Cytokine Gene Disruption And Exhibiting A Greater Susceptibility To A Cytokine-Mediated Autoimmune And/Or Inflammatory Disease
Genetically Modified Rat Comprising A Cytokine Gene Disruption And Exhibiting A Greater Susceptibility To A Cytokine-Mediated Autoimmune And/Or Inflammatory Disease
US Patent:
8558055, Oct 15, 2013
Filed:
Jul 23, 2010
Appl. No.:
12/842418
Inventors:
Eric M. Ostertag - Lexington KY, US
John Stuart Crawford - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Assignee:
Transposagen Biopharmaceuticals, Inc. - Lexington KY
International Classification:
C12N 15/00, A01K 67/033, A01K 67/027, G01N 33/00
US Classification:
800 13, 800 3, 800 25
Abstract:
The present invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are deficient due to the disruption of gene(s) or gene product(s) resulting in cytokine-cytokine mediated autoimmune and inflammatory disease. In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human autoimmune and inflammatory disease and methods of their use. Specifically, the invention pertains to a genetically altered rat, or a rat cell in culture, that is defective in at least one of two alleles of a cytokine gene such as the Faslg gene, the Fas gene, etc. In one embodiment, the cytokine gene is the Faslg gene. In another embodiment, the cytokine gene is one of several known cytokine genes, such as Fas, IFNγ, TNF-α, IL-2, IL-10, and IL-12. The inactivation of at least one of these cytokine alleles results in an animal with a higher susceptibility to cytokine-cytokine mediated autoimmune and inflammatory disease induction.
Trp Inhibitors And Uses Thereof
Trp Inhibitors And Uses Thereof
US Patent:
2012014, Jun 14, 2012
Filed:
Aug 20, 2010
Appl. No.:
13/391305
Inventors:
Eric M. Ostertag - Lexington KY, US
John Stuart Crawford - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Assignee:
TRANSPOSAGEN BIOPHARMACEUTICALS, INC. - Lexington KY
International Classification:
A61K 31/713, A61K 31/683, A61K 31/18, A61K 31/5415, A61K 31/135, A61K 31/404, A61K 31/352, A61K 38/02, A61K 31/522, A61K 31/133, A61K 31/165, A61K 31/69, A61K 31/4965, A61K 31/47, A61K 31/335, A61K 31/4375, A61K 31/047, A61K 31/7076, A61K 31/131, A61K 31/045, A61K 31/4164, A61K 31/44, A61K 31/28, A61K 31/285, C12Q 1/02, C12N 5/07, A61P 29/00, A61K 39/395
US Classification:
4241721, 514 44 A, 514103, 514602, 5142258, 5142248, 514649, 514414, 514456, 514 183, 514646, 51426334, 514669, 514604, 514627, 514 64, 5142521, 51425305, 514450, 514280, 514729, 514 46, 514674, 514724, 514396, 514277, 514492, 514504, 435 29, 435375
Abstract:
The present invention, relates to methods including compounds, derivatives, antibodies, interfering RNA, biologies, polypeptides, dominant negative effectors, and their use in the treatment of neuropathic pain by inhibition of transient receptor potential (TRP) channels. In another embodiment, this invention relates to inhibitors, antagonists, and agonists of TRPC4. TRPC4 therapeutic agents and modulators include but are not limited to small molecule inhibitors, compounds, amino acid derivatives, polypeptides, RNA interference agents, natural chemicals, ligand derivatives, and ions. TRPC4 therapeutic agents and modulators are developed for the treatment of neuropathic pain, including but not limited to pain sensations such as nociception, hyperalgesia, allodynia, and loss of sensory function.
Compositions And Methods For Separating, Characterizing And Administering Soluble Selenoglycoproteins
Compositions And Methods For Separating, Characterizing And Administering Soluble Selenoglycoproteins
US Patent:
2011028, Nov 17, 2011
Filed:
Mar 18, 2011
Appl. No.:
13/051646
Inventors:
Stefan Kwiatkowski - Lexington KY, US
Ronan Power - Lexington KY, US
Clayton Matney - Nicholasville KY, US
Paiman Peter Ghoroghchian - Downingtown PA, US
Eric Michael Ostertag - Lexington KY, US
Ronan Power - Lexington KY, US
Clayton Matney - Nicholasville KY, US
Paiman Peter Ghoroghchian - Downingtown PA, US
Eric Michael Ostertag - Lexington KY, US
Assignee:
ALLTECH, INC. - Nicholasville KY
International Classification:
A61K 9/48, A61K 38/14, C07K 14/00
US Classification:
424501, 530395, 514 209
Abstract:
The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e.g., via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.
Nucleic Acids Encoding Hyperactive Piggybac Transposases
Nucleic Acids Encoding Hyperactive Piggybac Transposases
US Patent:
8399643, Mar 19, 2013
Filed:
Feb 25, 2010
Appl. No.:
12/712504
Inventors:
Eric Ostertag - Lexington KY, US
Blair Madison - Philadelphia PA, US
Blair Madison - Philadelphia PA, US
Assignee:
Transposagen Biopharmaceuticals, Inc. - Lexington KY
International Classification:
C07H 21/04, C12N 5/00
US Classification:
536 232, 536 237, 4353201, 435325
Abstract:
The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.
Genetically Modified Rat Models For Severe Combined Immunodeficiency (Scid)
Genetically Modified Rat Models For Severe Combined Immunodeficiency (Scid)
US Patent:
2012017, Jul 12, 2012
Filed:
Jul 1, 2010
Appl. No.:
13/391307
Inventors:
Eric M. Ostertag - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Joseph Ruiz - Lexington KY, US
John Stuart Crawford - Lexington KY, US
Joseph Ruiz - Lexington KY, US
International Classification:
A61K 49/00, A01K 67/027
US Classification:
424 92, 800 9
Abstract:
This invention relates to the engineering of animal cells, preferably mammalian, more preferably rat, that are dencient due to the disruption of tumor suppressor gene(s) or gene product(s). In another aspect, the invention relates to genetically modified rats, as well as the descendants and ancestors of such animals, which are animal models of human cancer and methods of their use.
Compositions And Methods For Separating, Characterizing And Administering Soluble Selenoglycoproteins
Compositions And Methods For Separating, Characterizing And Administering Soluble Selenoglycoproteins
US Patent:
8575320, Nov 5, 2013
Filed:
Sep 16, 2011
Appl. No.:
13/235191
Inventors:
Stefan Kwiatkowski - Lexington KY, US
Ronan Power - Lexington KY, US
Clayton Matney - Nicholasville KY, US
Paiman Peter Ghoroghchian - Downingtown PA, US
Eric Michael Ostertag - Lexington KY, US
Ronan Power - Lexington KY, US
Clayton Matney - Nicholasville KY, US
Paiman Peter Ghoroghchian - Downingtown PA, US
Eric Michael Ostertag - Lexington KY, US
Assignee:
Alltech, Inc. - Nicholasville KY
International Classification:
C07K 1/00, A61K 36/06
US Classification:
530395, 530371
Abstract:
The invention relates to soluble selenium compositions and methods of production, separation and purification thereof. In particular the present invention provides methods of preparing water soluble selenoglycoproteins (e. g. , via extracting selenoglycoproteins from selenium enriched yeast), methods of supplementing a selenium deficient composition via admixing water soluble selenoglycoproteins with the selenium deficient composition, compositions comprising the water soluble selenoglycoproteins and methods of administering the same.
Hyperactive Piggybac Transposases
Hyperactive Piggybac Transposases
US Patent:
2013016, Jun 20, 2013
Filed:
Feb 22, 2013
Appl. No.:
13/774718
Inventors:
Eric Ostertag - Lexington KY, US
Blair Madison - Philadelphia PA, US
Blair Madison - Philadelphia PA, US
Assignee:
Transposagen Biopharmaceuticals, Inc. - Lexington KY
International Classification:
C12N 15/85, A61D 19/04
US Classification:
800 13, 435462, 800 21, 800 22, 600 34
Abstract:
The present invention provides PiggyBac transposase proteins, nucleic acids encoding the same, compositions comprising the same, kits comprising the same, non-human transgenic animals comprising the same, and methods of using the same.